{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:59:58Z","timestamp":1785344398412,"version":"3.55.0"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer with a poor prognosis, strongly associated with androgen deprivation therapy. Recent studies have revealed that neuroendocrine transdifferentiation in NEPC is influenced by both transcription factor activity and epigenetic regulation. This review systematically discusses the origin hypotheses, molecular subtypes, driving mechanisms, and therapeutic strategies of NEPC, focusing on the critical roles of transcription factors and epigenetic modifications in lineage plasticity. Furthermore, we summarize the latest advancements in targeted therapies. By integrating multiomics data and preclinical models, this review provides a theoretical foundation for precision treatment of NEPC.<\/jats:p>","DOI":"10.3389\/fonc.2026.1806742","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:41:20Z","timestamp":1776832880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanistic insights and molecular therapy for neuroendocrine prostate cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yichen","family":"Niu","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, First Affiliated Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Department of Urology, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.12.065","article-title":"Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate","volume":"20","author":"Papandreou","year":"2002","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.10.026","article-title":"Unusual and underappreciated: small cell carcinoma of the prostate","volume":"34","author":"Palmgren","year":"2007","journal-title":"Semin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.3553","article-title":"Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis","volume":"32","author":"Wang","year":"2014","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.212","article-title":"Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta-analysis","volume":"4","author":"Chen","year":"2023","journal-title":"BJUI Compass"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4341","article-title":"Biology and evolution of poorly differentiated neuroendocrine tumors","volume":"23","author":"Rickman","year":"2017","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/17.5.303","article-title":"The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept","volume":"17","author":"Pearse","year":"1969","journal-title":"J Histochem Cytochem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.09.007","article-title":"Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities","volume":"47","author":"Vashchenko","year":"2005","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0045(19990501)39:2<135::aid-pros9>3.0.co;2-s","article-title":"Neuroendocrine differentiation in prostatic carcinoma","volume":"39","author":"Abrahamsson","year":"1999","journal-title":"Prostate"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0304-3835(02)00413-5","article-title":"The role of androgens and the androgen receptor in prostate cancer","volume":"187","author":"Debes","year":"2002","journal-title":"Cancer Lett"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m108255200","article-title":"Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways","volume":"277","author":"Ueda","year":"2002","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(97)00308-0","article-title":"Neuroblastoma","volume":"33","author":"Castleberry","year":"1997","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.26.15382","article-title":"A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells","volume":"95","author":"Garabedian","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-015-0204-7","article-title":"Comprehensive serial molecular profiling of an \u201cN of 1\u201d exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment","volume":"8","author":"Kadakia","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30497-8","article-title":"Targeting lineage plasticity in prostate cancer","volume":"20","author":"Antonarakis","year":"2019","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1586\/era.12.127","article-title":"Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice","volume":"12","author":"Cheng","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-1174","article-title":"Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer","volume":"7","author":"Zou","year":"2017","journal-title":"Cancer Discov"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(06)00096-6","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.7","article-title":"ERG gene rearrangements are common in prostatic small cell carcinomas","volume":"24","author":"Lotan","year":"2011","journal-title":"Mod Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-08-2927","article-title":"Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States","volume":"15","author":"Mosquera","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1318-9","article-title":"FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes","volume":"571","author":"Adams","year":"2019","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci137967","article-title":"ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming","volume":"130","author":"Li","year":"2020","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2019-2099","article-title":"N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","volume":"129","author":"Berger","year":"2019","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.cd-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-0157","article-title":"SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/pas.0b013e318058a96b","article-title":"Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases","volume":"32","author":"Wang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840915)54:6<1043::aid-cncr2820540619>3.0.co;2-u","article-title":"Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. Immunohistochemical study and review of the literature","volume":"54","author":"Ghali","year":"1984","journal-title":"Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200606000-00005","article-title":"Small cell carcinoma of the prostate: an immunohistochemical study","volume":"30","author":"Yao","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200606000-00003","article-title":"Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer","volume":"30","author":"Evans","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.04.006","article-title":"Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis","volume":"15","author":"Zaffuto","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3155552","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance","volume":"3","author":"Deng","year":"2022","journal-title":"Nat Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3221","article-title":"Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue","volume":"47","author":"Cooper","year":"2015","journal-title":"Nat Genet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature06024","article-title":"Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer","volume":"448","author":"Tomlins","year":"2007","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1538-7445.am2011-2808","article-title":"Characterization of KRAS rearrangements in metastatic prostate cancer","volume":"1","author":"Wang","year":"2011","journal-title":"Cancer Discov"},{"key":"B58","article-title":"p53 is mutated in a subset of advanced-stage prostate cancers","volume":"53","author":"Bookstein","year":"1993","journal-title":"Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(01)67065-4","article-title":"Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer","volume":"154","author":"Heidenberg","year":"1995","journal-title":"J Urol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(01)00323-9","article-title":"Regulation of PTEN transcription by p53","volume":"8","author":"Stambolic","year":"2001","journal-title":"Mol Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s1535-6108(03)00021-7","article-title":"PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms","volume":"3","author":"Freeman","year":"2003","journal-title":"Cancer Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s1535-6108(03)00022-9","article-title":"PTEN and p53: who will get the upper hand","volume":"3","author":"Trotman","year":"2003","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature03918","article-title":"Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis","volume":"436","author":"Chen","year":"2005","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-0486","article-title":"Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer","volume":"66","author":"Zhou","year":"2006","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(03)01075-4","article-title":"Principles of tumor suppression","volume":"116","author":"Sherr","year":"2004","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"175","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/jci132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2068","article-title":"RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer","volume":"25","author":"Nava Rodrigues","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1530\/erc-11-0368","article-title":"Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway","volume":"19","author":"Chen","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02135-3","article-title":"RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition","volume":"41","author":"Han","year":"2022","journal-title":"Oncogene"},{"key":"B71","first-page":"397","article-title":"Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancer","volume":"10","author":"Qian","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14207","article-title":"Molecular model for neuroendocrine prostate cancer progression","volume":"122","author":"Chen","year":"2018","journal-title":"BJU Int"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.8","article-title":"A decade of transcription factor-mediated reprogramming to pluripotency","volume":"17","author":"Takahashi","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1101\/sqb.2010.75.061","article-title":"Nuclear mobility and mitotic chromosome binding: similarities between pioneer transcription factor FoxA and linker histone H1","volume":"75","author":"Zaret","year":"2010","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1242\/dev.01917","article-title":"Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation","volume":"132","author":"Gao","year":"2005","journal-title":"Development"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-006-6095-6","article-title":"The Foxa family of transcription factors in development and metabolism","volume":"63","author":"Friedman","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.018","article-title":"FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription","volume":"132","author":"Lupien","year":"2008","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41467-021-22139-7","article-title":"Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer","volume":"12","author":"Baca","year":"2021","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1038\/s41467-024-49234-9","article-title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.11.008","article-title":"Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity","volume":"9","author":"Cai","year":"2014","journal-title":"Cell Rep"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1038\/s41467-021-23780-y","article-title":"Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","first-page":"19076","DOI":"10.1038\/s41598-019-55665-y","article-title":"hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen","volume":"9","author":"Fraser","year":"2019","journal-title":"Sci Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104576","article-title":"Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3396","article-title":"Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer","volume":"27","author":"DeLucia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2023.06.006","article-title":"ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer","volume":"205","author":"Nie","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.043","article-title":"Control of developmental regulators by Polycomb in human embryonic stem cells","volume":"125","author":"Lee","year":"2006","journal-title":"Cell"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0041","article-title":"Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation","volume":"2","author":"Borno","year":"2012","journal-title":"Cancer Discov"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21112","article-title":"Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines","volume":"70","author":"Karanikolas","year":"2010","journal-title":"Prostate"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-2498","article-title":"A polycomb repression signature in metastatic prostate cancer predicts cancer outcome","volume":"67","author":"Yu","year":"2007","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"key":"B91","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41568-018-0003-x","article-title":"Too many targets, not enough patients: rethinking neuroblastoma clinical trials","volume":"18","author":"Fletcher","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-13-0536","article-title":"The N-myc oncogene: maximizing its targets, regulation, and therapeutic potential","volume":"12","author":"Beltran","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","article-title":"Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma","volume":"15","author":"Otto","year":"2009","journal-title":"Cancer Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0469","article-title":"Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov"},{"key":"B97","doi-asserted-by":"publisher","first-page":"8998","DOI":"10.1158\/0008-5472.can-08-2658","article-title":"Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells","volume":"68","author":"Dar","year":"2008","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41419-023-05894-x","article-title":"Neurokinin-1 receptor drives PKCa-AURKA\/N-Myc signaling to facilitate the neuroendocrine progression of prostate cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B99","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12929-021-00765-z","article-title":"Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models","volume":"28","author":"Sooreshjani","year":"2021","journal-title":"J BioMed Sci"},{"key":"B100","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3892\/ol.2020.12192","article-title":"Emerging role of ONECUT2 in tumors","volume":"20","author":"Yu","year":"2020","journal-title":"Oncol Lett"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae547","article-title":"ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer","volume":"52","author":"Qian","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-024-00957-3","article-title":"ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity","volume":"48","author":"Zamora","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1273638","article-title":"Roles of retrovirus-derived PEG10 and PEG11\/RTL1 in mammalian development and evolution and their involvement in human disease","volume":"11","author":"Shiura","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115600","article-title":"The placental gene PEG10 promotes progression of neuroendocrine prostate cancer","volume":"12","author":"Akamatsu","year":"2015","journal-title":"Cell Rep"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.7150\/thno.92336","article-title":"Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression","volume":"14","author":"Zhang","year":"2024","journal-title":"Theranostics"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107617","article-title":"SHOX2 promotes prostate cancer proliferation and metastasis through disruption of the Hippo-YAP pathway","volume":"26","author":"Yang","year":"2023","journal-title":"iScience"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184355","article-title":"Early dynamics of quantitative SEPT9 and SHOX2 methylation in circulating cell-free plasma DNA during prostate biopsy for prostate cancer diagnosis","volume":"14","author":"Krausewitz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030482","article-title":"Feasibility of monitoring response to metastatic prostate cancer treatment with a methylation-based circulating tumor DNA approach","volume":"16","author":"Buttner","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10045","article-title":"Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation","volume":"50","author":"Waltregny","year":"2002","journal-title":"Prostate"},{"key":"B110","article-title":"Aberrant HOXC expression accompanies the Malignant phenotype in human prostate","volume":"63","author":"Miller","year":"2003","journal-title":"Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.mcr-10-0111","article-title":"HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes","volume":"8","author":"Axlund","year":"2010","journal-title":"Mol Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20443","article-title":"PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation","volume":"66","author":"Kikugawa","year":"2006","journal-title":"Prostate"},{"key":"B113","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41467-018-08152-3","article-title":"IRE1alpha-XBP1s pathway promotes prostate cancer by activating c-MYC signaling","volume":"10","author":"Sheng","year":"2019","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/erc-19-0181","article-title":"Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program","volume":"27","author":"Stelloo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"788","DOI":"10.15252\/emmm.201404509","article-title":"Divergent androgen regulation of unfolded protein response pathways drives prostate cancer","volume":"7","author":"Sheng","year":"2015","journal-title":"EMBO Mol Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00723","article-title":"Early treatment intensification in metastatic hormone-sensitive prostate cancer","volume":"41","author":"Wala","year":"2023","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr Rev"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34490","article-title":"Antibody-drug conjugates in prostate cancer: a systematic review","volume":"15","author":"Sardinha","year":"2023","journal-title":"Cureus"},{"key":"B125","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.04.008","article-title":"Outcomes of second-line therapies in patients with metastatic de novo and treatment-emergent neuroendocrine prostate cancer: a multi-institutional study","volume":"21","author":"Eule","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6732","article-title":"Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer","volume":"15","author":"Yamada","year":"2023","journal-title":"Sci Transl Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1172\/jci162148","article-title":"Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models","volume":"133","author":"Agarwal","year":"2023","journal-title":"J Clin Invest"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.09.164","article-title":"Inhibition of LSD1 by pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo","volume":"467","author":"Wang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34366","article-title":"Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced Malignancies","volume":"128","author":"Hollebecque","year":"2022","journal-title":"Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2380","article-title":"Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin lymphoma","volume":"27","author":"Hollebecque","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24707","article-title":"Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models","volume":"84","author":"Jasmine","year":"2024","journal-title":"Prostate"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-0317","article-title":"PARP inhibition suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine differentiation in castration-resistant prostate cancer","volume":"25","author":"Liu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-20-0848","article-title":"PARP and CDK4\/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer","volume":"20","author":"Wu","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.652303","article-title":"Danusertib, an aurora kinase inhibitor","volume":"21","author":"Meulenbeld","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"B138","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1078-0432.ccr-17-1872","article-title":"Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.ccr-18-1912","article-title":"A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"3929\u2013","DOI":"10.1158\/1538-7445.am2022-3929","article-title":"Abstract 3929: Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction","volume":"82","author":"Gavory","year":"2022","journal-title":"Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633579","article-title":"Control analysis of protein-protein interaction network reveals potential regulatory targets for MYCN","volume":"11","author":"Pan","year":"2021","journal-title":"Front Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10290","article-title":"MHC class I antigens, immune surveillance, and tumor immune escape","volume":"195","author":"Garcia-Lora","year":"2003","journal-title":"J Cell Physiol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0045(19971201)33:4<233::aid-pros2>3.0.co;2-i","article-title":"MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma","volume":"33","author":"Bander","year":"1997","journal-title":"Prostate"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.4.280","article-title":"Molecular characterization of defective antigen processing in human prostate cancer","volume":"87","author":"Sanda","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"B147","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/eji.200324610","article-title":"Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells","volume":"34","author":"Coccia","year":"2004","journal-title":"Eur J Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-323-31696-5.00019-x","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.30","article-title":"The functions of tumor suppressor PTEN in innate and adaptive immunity","volume":"14","author":"Chen","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"7736","DOI":"10.1038\/ncomms8736","article-title":"STAT3 regulated ARF expression suppresses prostate cancer metastasis","volume":"6","author":"Pencik","year":"2015","journal-title":"Nat Commun"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-24-1388","article-title":"Neuroendocrine differentiation in prostate cancer requires ASCL1","volume":"84","author":"Rodarte","year":"2024","journal-title":"Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00838-6","article-title":"The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1","volume":"5","author":"Romero","year":"2024","journal-title":"Nat Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-24-2913","article-title":"ASCL1 drives the development of neuroendocrine prostate cancer","volume":"84","author":"McQuillen","year":"2024","journal-title":"Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.52843\/cassyni.b3jrfx","article-title":"Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer","volume":"83","author":"Chou","year":"2023","journal-title":"Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2203820119","article-title":"Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer","volume":"119","author":"Korsen","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00249-3","article-title":"Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1\/2, first-in-human trial","volume":"25","author":"Tendler","year":"2024","journal-title":"Lancet Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121497","article-title":"Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer","volume":"3","author":"Su","year":"2018","journal-title":"JCI Insight"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:41:25Z","timestamp":1776832885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":160,"alternative-id":["10.3389\/fonc.2026.1806742"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1806742","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1806742"}}